Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;11(Suppl 7):S969-S975.
doi: 10.21037/jtd.2019.04.09.

Evidence for surgical resections in oligometastatic lung cancer

Rafael A S Fernandez  1 , Rainbow W H Lau  1 , Jacky Y K Ho  1 , Peter S Y Yu  1 , Simon C Y Chow  1 , Innes Y P Wan  1 , Calvin S H Ng  1
Affiliations
Review

Evidence for surgical resections in oligometastatic lung cancer

Rafael A S Fernandez et al. J Thorac Dis. 2019 Apr.

Abstract

With the advent of advanced technology in performing diagnostics for lung cancer, an incremental increase in the number of patients with oligometastatic disease is currently being managed with intent to cure. As treatment of selected types of patients with oligometastasis show favourable outcomes, the past notion of managing these patients palliatively is fast becoming extinct. Selection of patients based on established criterion together with surgical metastasectomy combined with multiple ablative techniques with or without systemic chemotherapy offers a reasonable rate of treatment success which provides basis for treating such patient population. As more evidence becomes available to suggest that the oligometastatic state of lung cancer does exist, and are potentially curable, a better understanding of the condition is necessary for clinicians, and surgeons to provide optimal care. In this review we present some of the clinical basis which may cause a paradigm shift in management of patients with oligometastatic lung disease.

Keywords: Lung cancer; metastases; oligometastases.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Calvin S. H. Ng is a consultant for Johnson and Johnson and Medtronic, USA. Other authors have no conflicts of interest to declare.

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. 10.1200/JCO.1995.13.1.8 - DOI - PubMed
    1. Niibe Y, Hayakawa K. Oligometastases and Oligo-recurrence: The New Era of Cancer Therapy. Jpn J Clin Oncol 2010;40:107-111. 10.1093/jjco/hyp167 - DOI - PMC - PubMed
    1. Li S, Zhu R, Li D, et al. Prognostic factors of oligometastatic non-small cell lung cancer: a meta-analysis. J Thorac Dis 2018;10:3701-13. 10.21037/jtd.2018.05.105 - DOI - PMC - PubMed
    1. Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113:37-49. 10.1016/S0022-5223(97)70397-0 - DOI - PubMed
    1. Goldstraw P, Chansky K, Crowley J, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions ; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11:39-51 10.1016/j.jtho.2015.09.009 - DOI - PubMed